With the lords a-leaping, the industry is set to spring forward in 2026. Ricky Lakhani, chief product officer at Pharmaseal, reflects on a year of consolidation and shares his hopes and predictions for the year ahead, shining a light on AI, efficiency, and the next wave of life sciences innovation.

Hopes and predictions for 2026

As we turn the page on a year of consolidation, I hope 2026 promises to be the year of resurgence. I hope the resiliency forged in 2025 will serve as the foundation for a revitalised life sciences landscape. We predict a distinct upturn in the industry, characterised by renewed investment confidence and a significant upturn in trial startups. However, this growth will be smarter, and my hope and prediction is that companies will embrace digital standards and technologies.

My deepest hope for 2026 lies in the maturation of Artificial Intelligence. We must evolve beyond the early, primitive applications of AI to truly transformative implementations. The objective is clear: leverage AI to radically streamline processes and eliminate the manual burden of mundane activities. By trusting technology to handle the routine, we free our industry’s experts to focus on what matters most—empowering the next generation of life-saving treatments for patients.

For PHARMASEAL, my aspiration is that we continue to increase our visibility as a forward-thinking, modern software provider that champions these digital standards for the betterment of the industry. We will continue to innovate and deepen our partnerships with both current and prospective customers, ensuring that Engility remains the agile, central hub of clinical research.

2026 is the year we turn efficiency into acceleration.